NMS-03597812 + dexamethasone

NMS-03597812 is an investigational small molecule inhibitor targeting PERK (PKR-like endoplasmic reticulum kinase, also known as EIF2AK4), developed by Nerviano Medical Sciences. It is being studied for its antineoplastic activity in relapsed or refractory multiple myeloma and acute myeloid leukemia. Dexamethasone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressant properties, acting primarily as a glucocorticoid receptor agonist. The combination of NMS-03597812 and dexamethasone is under evaluation in early-phase clinical trials for patients with relapsed or refractory multiple myeloma who have exhausted standard treatment options[1][3][4][6][8].